Enhancing Safety and Quality of Care for Parkinson’s Disease Patients Hospitalized at a Large Academic Medical Center
Objective: To implement measures to improve quality of care in Parkinson's disease (PD) patients who are hospitalized at a large academic hospital with the goal…Medication Error Reduction Strategies in an In-patient Multimodal Intensive Neurorehabilitation and Care (i-MINC) Program
Objective: To evaluate medication safety strategies implemented to reduce medication errors in an i-MINC Program Background: Medication mismanagement may lead to critical patient harm in…A Phase I Study of TR-012001, a Nasal Levodopa, in Healthy Adult Japanese Male Subjects
Objective: To investigate the safety, tolerability, and pharmacokinetics of TR-012001, a nasal levodopa (LD), in healthy Japanese adult men with and without premedication with dopa…Effect of COVID-19 Pandemic on Utilization of Parkinson’s Medications in Saudi Arabia: A Repeated Cross-Sectional Study
Objective: This study aims to examine the effects of the pandemic on the patterns of medication usage for Parkinson’s Disease (PD) in Saudi Arabia. Background:…Neuroprotective Action of Betulin in Parkinson’s disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model
Objective: The objective of this study was to evaluate the neuroprotective efficacy of Betulin in MPTP-induced mice models of Parkinson's disease (PD), focusing on its…Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity
Objective: To evaluate the perceptivity of mTOR kinase activity inhibition for Parkinson's disease therapy (PD). Background: The protein kinase mTOR is currently considered as a…Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data
Objective: To evaluate 12-month adherence and persistence and identify factors associated with persistence among Parkinson’s disease (PD) patients initiating istradefylline, the first non-dopaminergic adjunct targeting…Carbidopa does not cause changes in QTc interval even at a supratherapeutic dose
Objective: To assess the cardiac safety of a single supratherapeutic dose of carbidopa in healthy adults. Background: Carbidopa has been approved for use in combination…Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson’s Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.
Objective: To perform a systematic review and meta-analysis on recruitment of people with Parkinson’s disease (PwP, PD) from different ethnic and racial groups in disease-modifying…Clinical characteristics associated with early discontinuation of Levodopa-Carbidopa Intestinal Gel infusion in patients with advanced Parkinson Disease.
Objective: To determine the clinical characteristics associated with early withdrawal of Levodopa-Carbidopa Intestinal Gel infusion (LCIG) in patients with advanced Parkinson´s Disease (APD) Background: LCIG…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 36
- Next Page »